US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

15.10

-0.1675-1.10%

Volume:71.39K

Turnover:1.08M

Market Cap:1.94B

PE:-4.61

High:15.40

Open:15.12

Low:15.10

Close:15.27

52wk High:22.67

52wk Low:11.00

Shares:128.19M

Float Shares:60.29M

Volume Ratio:1.14

T/O Rate:0.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2762

EPS(LYR):-4.9816

ROE:-81.72%

ROA:-34.63%

PB:4.25

PE(LYR):-3.03

Loading ...

Overview Company News Filings

Generate Biomedicines is Maintained at Buy by HC Wainwright & Co.

U.S. Research Roundup-Dollar General, Palo Alto, Workday

Small U.S. Stocks Finish Mixed as Abercrombie & Fitch Leads, Generate Biomedicines Lags

Generate Biomedicines falls -16.7%

Generate Biomedicines Starts Phase 3 Solairia Trials of GB-0895 in Severe Uncontrolled Asthma

Generate Biomedicines rises 17.7%

Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)

Generate Biomedicines Shares Fall Following Q2 Financial Results

MT Newswires Live

Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate

Benzinga Earnings

Generate Biomedicines - Q2 Revenue $6.30 Mln

THOMSON REUTERS

Generate Biomedicines: Existing Cash, Cash Equivalents, and Marketable Securities Sufficient to Fund Current Operating Plan into H1 2028

THOMSON REUTERS

Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million

Generate Biomedicines Releases Corporate Presentation on Programmable Biology Platform and Clinical-stage Pipeline

Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK hynix Inc. Sponsored GDR (OtherHXSCL)

Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)

Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x

Simply Wall St.

Generate Biomedicines to present at Goldman Sachs Global Healthcare Conference

Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

Stock Track | Generate Biomedicines Soars 5.29% Intraday Following Nvidia's $10.4 Million Investment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/GENB/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GENB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":15.1025,"timestamp":1788269866202,"preClose":15.27,"halted":0,"volume":71388,"delay":0,"changeRate":-0.010969220694171606,"floatShares":60288200,"shares":128192484,"eps":-3.27625,"marketStatus":"Trading","change":-0.1675,"latestTime":"09-01 09:37:48 EDT","open":15.12,"high":15.4,"low":15.095,"amount":1082672.049924,"amplitude":0.019974,"askPrice":15.18,"askSize":200,"bidPrice":15.04,"bidSize":116,"shortable":3,"etf":0,"ttmEps":-3.27625,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788292800000},"marketStatusCode":2,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":15.27,"preHourTrading":{"tag":"盘前","latestPrice":15,"preClose":15.27,"latestTime":"09:20 EDT","volume":8136,"amount":123796.96919999999,"timestamp":1788268834987,"change":-0.27,"changeRate":-0.017682,"amplitude":0.045318},"postHourTrading":{"tag":"盘后","latestPrice":15.35,"preClose":15.27,"latestTime":"19:44 EDT","volume":9271,"amount":140579.348,"timestamp":1788219881115,"change":0.08,"changeRate":0.005239,"amplitude":0.019646},"volumeRatio":1.136587},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","floatShares":60288200,"roa":"-34.63%","roe":"-81.72%","lyrEps":-4.981642,"volumeRatio":1.136587,"shares":128192484,"dividePrice":0,"high":15.4,"amplitude":0.019974,"preClose":15.27,"low":15.095,"week52Low":11,"pbRate":"4.25","psRate":"73.10","week52High":22.6699,"institutionHeld":0,"latestPrice":15.1025,"committee":-0.265823,"eps":-3.27625,"divideRate":0,"volume":71388,"delay":0,"ttmEps":-3.27625,"open":15.12,"prevYearClose":16,"prevWeekClose":15.33,"prevMonthClose":15.27,"prevQuarterClose":16.87,"fiveDayClose":20.38,"twentyDayClose":14.28,"sixtyDayClose":12.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GENB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"GENB","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2026-05-07","symbol":"GENB","fiscalQuarterEnding":"2026/03","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GENB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GENB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1782532800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GENB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GENB","date":"2026-08-31","current":-4.609691,"percent":0.309524,"low":-11.002825,"twenty":-8.698603,"median":-7.976268,"eighty":-7.531161,"high":-6.883628,"avg":-8.152533,"sd":0.750188,"marketCap":1967642843},"quantilePoints":[{"date":"2026-02-27","current":-10.037721,"twenty":-10.037721,"median":-10.037721,"eighty":-10.037721,"marketCap":2039203216},{"date":"2026-03-06","current":-7.810602,"twenty":-7.936073,"median":-7.722772,"eighty":-7.484376,"marketCap":1586755002},{"date":"2026-03-13","current":-8.331309,"twenty":-7.979988,"median":-7.660036,"eighty":-7.484376,"marketCap":1692538669},{"date":"2026-03-20","current":-7.710225,"twenty":-7.979988,"median":-7.68513,"eighty":-7.484376,"marketCap":1566362970},{"date":"2026-03-27","current":-8.061545,"twenty":-7.979988,"median":-7.697677,"eighty":-7.484376,"marketCap":1637735082},{"date":"2026-04-02","current":-8.350129,"twenty":-7.996299,"median":-7.697677,"eighty":-7.419131,"marketCap":1696362175},{"date":"2026-04-10","current":-7.233433,"twenty":-7.996299,"median":-7.647489,"eighty":-7.419131,"marketCap":1469500817},{"date":"2026-04-17","current":-7.910979,"twenty":-8.036451,"median":-7.697677,"eighty":-7.419131,"marketCap":1607147034},{"date":"2026-04-24","current":-8.067818,"twenty":-8.0628,"median":-7.732183,"eighty":-7.42164,"marketCap":1639009584},{"date":"2026-05-01","current":-7.923526,"twenty":-8.036451,"median":-7.810602,"eighty":-7.471829,"marketCap":1609696038},{"date":"2026-05-08","current":-8.522653,"twenty":-8.180743,"median":-7.816876,"eighty":-7.489394,"marketCap":1731410980},{"date":"2026-05-15","current":-8.844872,"twenty":-8.266063,"median":-7.84197,"eighty":-7.500687,"marketCap":1971654609},{"date":"2026-05-22","current":-8.039526,"twenty":-8.266063,"median":-7.83256,"eighty":-7.486839,"marketCap":1792130926},{"date":"2026-05-29","current":-7.527711,"twenty":-8.282375,"median":-7.816876,"eighty":-7.489371,"marketCap":1678039615},{"date":"2026-06-05","current":-8.453579,"twenty":-8.282375,"median":-7.810602,"eighty":-7.474106,"marketCap":1884429514},{"date":"2026-06-12","current":-7.435699,"twenty":-8.229473,"median":-7.788352,"eighty":-7.435629,"marketCap":1657528818},{"date":"2026-06-18","current":-7.976268,"twenty":-8.211907,"median":-7.788092,"eighty":-7.435594,"marketCap":1778029753},{"date":"2026-06-26","current":-9.442705,"twenty":-8.343203,"median":-7.810602,"eighty":-7.4449,"marketCap":2104920587},{"date":"2026-07-02","current":-9.488711,"twenty":-8.508838,"median":-7.810602,"eighty":-7.463837,"marketCap":2115175986},{"date":"2026-07-10","current":-9.040154,"twenty":-8.869967,"median":-7.84197,"eighty":-7.484992,"marketCap":2015185848},{"date":"2026-07-17","current":-7.855502,"twenty":-8.85402,"median":-7.855502,"eighty":-7.488094,"marketCap":1751109331},{"date":"2026-07-24","current":-7.953265,"twenty":-8.801131,"median":-7.883241,"eighty":-7.493159,"marketCap":1772902053},{"date":"2026-07-31","current":-8.06828,"twenty":-8.626167,"median":-7.861253,"eighty":-7.503197,"marketCap":1798540550},{"date":"2026-08-07","current":-7.489636,"twenty":-8.522653,"median":-7.910979,"eighty":-7.503197,"marketCap":1780593602},{"date":"2026-08-14","current":-8.114449,"twenty":-8.453579,"median":-7.917253,"eighty":-7.52196,"marketCap":1929137113},{"date":"2026-08-21","current":-8.632737,"twenty":-8.626167,"median":-7.947085,"eighty":-7.52196,"marketCap":2052355451},{"date":"2026-08-28","current":-8.513962,"twenty":-8.702922,"median":-7.964766,"eighty":-7.527711,"marketCap":2024117915},{"date":"2026-08-31","current":-8.276414,"twenty":-8.698603,"median":-7.976268,"eighty":-7.531161,"marketCap":1967642843}],"updateTime":1788269868121},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GENB\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662706183","title":"Generate Biomedicines is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706183","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662706183?lang=en_us&edition=fundamental","pubTime":"2026-08-28 18:17","pubTimestamp":1787912220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GENB/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662905727","title":"U.S. Research Roundup-Dollar General, Palo Alto, Workday","url":"https://stock-news.laohu8.com/highlight/detail?id=2662905727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662905727?lang=en_us&edition=fundamental","pubTime":"2026-08-28 16:12","pubTimestamp":1787904773,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Dollar General, Palo Alto, WorkdayAug 28 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Dollar Gene","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nL4N44P0JD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THFF","AFRM","3NVD.UK","CUE","DG","PANW","A","KR","CRWD","BBY","KFY","MLM","CHH","HEI","RBRK","MBRX","AVAH","TTXU","IGV","UMBF","MRVL","RJF","NVDQ","THC","AXTA","DLTR","NVDA","NVDY","TOL","ALL","GAP","NVDW","AVNW","FSLR","HPQ","BURL","DY","ADSK","PALU","BBW","HAKY","ULTA","JAZZ","GENB","CRM","CRMG","MRNA","P","MISL","CBSH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662441897","title":"Small U.S. Stocks Finish Mixed as Abercrombie & Fitch Leads, Generate Biomedicines Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2662441897","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662441897?lang=en_us&edition=fundamental","pubTime":"2026-08-27 04:21","pubTimestamp":1787775660,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies were mixed Wednesday, as the Russell 2000 Index fell 0.1%, while the S&P Small Cap 600 Index was up 0.1%.Among companies with a market value of $1 billion to $6.7 billion, Generate Biomedicines Inc. was the biggest laggard during the session, dropping 21%, followed by shares of Evolution Metals & Technologies Corp., which dropped 15%. Shares of Advasa Holdings Inc. dropped 14%, Climb Bio Inc. shares tumbled 9.9%, and Horizon Quantum Holdings Ltd. tumbled 8.9%.Abercrombie & Fitch Co. was the best performer, surging 36%, followed by Biohaven Ltd., which surged 18%. Seaport Therapeutics Inc. shares surged 12%, WEBTOON Entertainment Inc. surged 11%, and shares of SolarEdge Technologies Inc. jumped 11%.Major stock indexes in the U.S. ended Wednesday mixed with the Nasdaq Composite Index dropping 0.1%. Meanwhile, the S&P 500 Index was flat, and the Dow Jones Industrial Average dropped 0.2%.Data ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4094","BK4585","BK4139","ANF","BK4588","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662301745","title":"Generate Biomedicines falls -16.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662301745","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662301745?lang=en_us&edition=fundamental","pubTime":"2026-08-27 00:05","pubTimestamp":1787760329,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB) is down -16.7%, or -$3.41 to $16.97. Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-falls-16-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-falls-16-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662179783","title":"Generate Biomedicines Starts Phase 3 Solairia Trials of GB-0895 in Severe Uncontrolled Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662179783","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662179783?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:04","pubTimestamp":1787738650,"startTime":"0","endTime":"0","summary":"Generate Biomedicines starts Phase 3 SOLAIRIA trials of GB-0895 in severe uncontrolled asthmaGenerate Biomedicines presented Phase 1 data for GB-0895, a long-acting anti-TSLP antibody being developed ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL34dPBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662974756","title":"Generate Biomedicines rises 17.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662974756","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662974756?lang=en_us&edition=fundamental","pubTime":"2026-08-26 00:06","pubTimestamp":1787673970,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB) is up 17.7%, or $3.14 to $20.86. Published first on TheFly – the ultimate source for real-time, market-moving breaking...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-rises-17-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-rises-17-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660480079","title":"Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660480079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660480079?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:57","pubTimestamp":1786971473,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Sean Laaman maintained a Buy rating on Generate Biomedicines, Inc. today and set a price target of $22.00. Laaman covers the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-buy-rating-for-generate-biomedicines-inc-genb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-buy-rating-for-generate-biomedicines-inc-genb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651586","title":"Generate Biomedicines Shares Fall Following Q2 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651586","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651586?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:51","pubTimestamp":1786038678,"startTime":"0","endTime":"0","summary":"Generate Biomedicines  shares fell 4.6% in Thursday trading after the company posted a wider-than-expected Q2 net loss and lower revenue.The company reported Q2 net loss of $0.52 per diluted share, narrowing from a loss of $1.94 a year earlier.Four analysts surveyed by FactSet expected a loss of $0.50.Collaboration revenue for the quarter ended June 30 was $6.3 million, down from $10.1 million a year ago.Three analysts expected $5.5 million.Price: 13.83, Change: -0.66, Percent Change: -4.55","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657763559","title":"Generate Biomedicines Q2 EPS $(0.52) Beats $(0.57) Estimate, Sales $6.314M Miss $6.625M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657763559","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657763559?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:37","pubTimestamp":1786016249,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (NASDAQ:GENB) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.57) by 8.77 percent. This is a 73.2 percent increase over losses of $(1.94) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60989852/generate-biomedicines-q2-eps-0-52-beats-0-57-estimate-sales-6-314m-miss-6-625m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638243","title":"Generate Biomedicines - Q2 Revenue $6.30 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638243","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638243?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA31F9SL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657382486","title":"Generate Biomedicines: Existing Cash, Cash Equivalents, and Marketable Securities Sufficient to Fund Current Operating Plan into H1 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2657382486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657382486?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014007,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA31F9SL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638623","title":"Press Release: Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638623","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638623?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014000,"startTime":"0","endTime":"0","summary":"studies continue to advance. To date, the studies have received. regulatory approvals in 33 countries as part of a planned 42-country. development program. Additional approvals are ongoing, and recruitment is","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657682336","title":"Generate Biomedicines Q2 FY26 Net Loss Widens to $67.26 Million; Revenue Drops to $6.31 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657682336","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657682336?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:11","pubTimestamp":1786011111,"startTime":"0","endTime":"0","summary":"Generate Biomedicines Q2 FY26 net loss widens to $67.26 million; revenue drops to $6.31 millionGenerate Biomedicines posted a GAAP net loss of $67.26 million for the quarter ended June 30, 2026, widen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL8LfD7q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2468319806.SGD","LU0122379950.USD","LU2089984988.USD","LU2242652126.USD","IE00B4R5TH58.HKD","LU2242646821.SGD","LU1571399168.USD","BK4534","IE0002141913.USD","BK4581","IE0009355771.USD","BK4588","IE00BJJMRZ35.SGD","LU1057294990.SGD","PBE","PJP","TBXU","BIB","LU0289739699.SGD","LU1061106388.HKD","LU0109394709.USD","BK4139","BK4585","LU1023059063.AUD","LU0868494617.USD","IBB","AMGN","LU0058720904.USD","IBBQ","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4566","BK4533","LU2112291526.USD","BK4599","IE00BJT1NW94.SGD","GENB","LU0320765992.SGD","SG9999001440.SGD","BBH","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647430327","title":"Generate Biomedicines Releases Corporate Presentation on Programmable Biology Platform and Clinical-stage Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2647430327","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647430327?lang=en_us&edition=fundamental","pubTime":"2026-06-29 23:47","pubTimestamp":1782748043,"startTime":"0","endTime":"0","summary":"Generate Biomedicines releases corporate presentation on programmable biology platform and clinical-stage pipelineGenerate Biomedicines highlighted GB-0895, an anti-TSLP monoclonal antibody in Phase 3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL9Yj1vn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646708218","title":"Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK hynix Inc. Sponsored GDR (OtherHXSCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646708218","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646708218?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:50","pubTimestamp":1782388209,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 3 analysts just weighed in on Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-yesway-inc-class-a-yswy-generate-biomedicines-inc-genb-and-sk-hynix-inc-sponsored-gdr-otherhxscl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-yesway-inc-class-a-yswy-generate-biomedicines-inc-genb-and-sk-hynix-inc-sponsored-gdr-otherhxscl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRAM","EEMO","SK","BK4113","BK4585","YSWY","GENB","BK4139","NA","RAM","EMXC","BK4588","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643127072","title":"Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643127072","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643127072?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:08","pubTimestamp":1781521690,"startTime":"0","endTime":"0","summary":"In a report released today, Seamus Fernandez from Guggenheim maintained a Buy rating on Generate Biomedicines, Inc., with a price target of $30.00....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-generate-biomedicines-inc-genb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-generate-biomedicines-inc-genb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640952990","title":"Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x","url":"https://stock-news.laohu8.com/highlight/detail?id=2640952990","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640952990?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:19","pubTimestamp":1780312753,"startTime":"0","endTime":"0","summary":"Stock performance snapshot\nGenerate Biomedicines (GENB) has drawn attention after recent trading, with the stock last closing at $13.12 and showing a mixed pattern over different periods, including a small move over the past month and a gain over the past 3 months.\nSee our latest analysis for Generate Biomedicines.\nRecent trading has been choppy, with a 7 day share price return of down 9.7% contrasting with a 90 day share price return of up 10.0%. This suggests short term momentum is cooling...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-genb/generate-biomedicines/news/assessing-generate-biomedicines-genb-valuation-as-losses-mou","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-genb/generate-biomedicines/news/assessing-generate-biomedicines-genb-valuation-as-losses-mou","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639661666","title":"Generate Biomedicines to present at Goldman Sachs Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639661666","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639661666?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:14","pubTimestamp":1779999240,"startTime":"0","endTime":"0","summary":"Generate Biomedicines will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL7ddLlq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0004091025.USD","LU1868836591.USD","LU0096364046.USD","LU2237443465.HKD","IE00B19Z3B42.SGD","LU1868836757.USD","LU2237443895.HKD","IE00BSNM7G36.USD","BK4585","LU2237443978.SGD","LU1668664300.SGD","LU0942090050.USD","LU0345770308.USD","LU2471134523.USD","GSX","LU1868837300.USD","GENB","BK4550","LU1804176565.USD","LU1894683264.USD","LU0106831901.USD","LU0742534661.SGD","LU0251142724.SGD","LU1868836914.USD","LU0868494617.USD","IE00B19Z3581.USD","LU0061475181.USD","LU1894683348.USD","LU2750360997.AUD","BK4504","BK4139","IE0034235188.USD","LU2750360641.GBP","BK4588","LU2237443549.SGD","LU2237443622.USD","BK4516","BK4552","LU2265009873.SGD","LU0251131958.USD","LU2471134796.USD","LU1868837136.USD","LU2471134952.CNY","LU0868494708.USD","BK4533","LU1791807156.HKD","IE0004086264.USD","IE00BFXG1179.USD","BK4127","LU2471134879.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638542062","title":"Generate Biomedicines publishes corporate presentation on programmable biology drug design platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2638542062","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638542062?lang=en_us&edition=fundamental","pubTime":"2026-05-27 03:24","pubTimestamp":1779823440,"startTime":"0","endTime":"0","summary":"Generate Biomedicines highlighted GB-0895, a half-life extended anti-TSLP monoclonal antibody, with Phase 3 studies initiated for severe asthma.Program targets twice-yearly dosing via a single subcutaneous injection; femtomolar TSLP binding affinity of 106 fM, cited as 20x stronger than tezepelumab.Pipeline update flagged five computationally engineered clinical-stage or clinic-ready molecules; eight programs have reached candidate nomination.Cash balance totaled USD 221.5 million at year-end 2025; management framed a catalyst-heavy 12-24 month window led by GB-0895 readouts.Other near-term clinical starts include GB-4362 in metastatic urothelial cancer, GB-5267 in platinum-resistant ovarian cancer, both targeted for 1H26 initiation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpret","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL4gbwpM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117754821","title":"Stock Track | Generate Biomedicines Soars 5.29% Intraday Following Nvidia's $10.4 Million Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=1117754821","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117754821?lang=en_us&edition=fundamental","pubTime":"2026-05-22 21:32","pubTimestamp":1779456750,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB) experienced a significant intraday surge of 5.29% on Friday, drawing attention to the AI-focused biotech company.The stock movement follows Nvidia's recent $10.4 million...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}]}}